{"id":988239,"date":"2026-08-03T05:03:01","date_gmt":"2026-08-03T09:03:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-appointment-of-guido-oelkers-to-management-board-as-chief-executive-officer\/"},"modified":"2026-08-03T05:03:01","modified_gmt":"2026-08-03T09:03:01","slug":"biontech-announces-appointment-of-guido-oelkers-to-management-board-as-chief-executive-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-appointment-of-guido-oelkers-to-management-board-as-chief-executive-officer\/","title":{"rendered":"BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer"},"content":{"rendered":"
\n

\n Mainz, Germany, August 3, 2026 (GLOBE NEWSWIRE)<\/b> \u2013 BioNTech SE<\/a> (Nasdaq: BNTX, \u201cBioNTech\u201d or \u201cthe Company\u201d) announced today that its Supervisory Board has appointed Guido Oelkers, Ph.D., to the Management Board as Chief Executive Officer (\u201cCEO\u201d), who will take office by February 1, 2027, at the latest. Succeeding Prof. Ugur Sahin, M.D., Guido Oelkers will join BioNTech from the global Nasdaq Stockholm-listed biopharmaceutical company Swedish Orphan Biovitrum AB (STO: SOBI, \u201cSobi\u201d), where he has served as CEO since 2017.<\/p>\n

Guido Oelkers is a seasoned CEO and strategic leader with over 30 years of experience in the biotechnology and pharmaceutical industries. He has a strong track record in transforming and scaling global organizations, driving sustainable growth through disciplined execution, focused capital allocation, and operational excellence. Throughout his career, Guido Oelkers has successfully built, prioritized and strengthened complex and innovative product portfolios across multiple areas, including oncology and immunology, while driving strong global business operations in key markets, notably in the United States.<\/p>\n

\u201cGuido Oelkers is an experienced executive in the pharmaceutical industry. Throughout his impressive international career, he has consistently demonstrated sound strategic leadership in global organizations, seamlessly transforming scientific excellence into commercial success,\u201d said Helmut Jeggle, Chairman of the Supervisory Board of BioNTech<\/b>. \u201cHis expertise in scaling innovation-driven organizations in a focused and capital-efficient manner, coupled with his deep knowledge in relevant markets, will position the Company well to deliver on its key objectives to become a multi-product company, and continue BioNTech\u2019s remarkable success story.\u201d<\/p>\n

\u201cBioNTech stands out through its scientific foundation and particularly its strong late-stage oncology pipeline,\u201d said Guido Oelkers, Ph.D., designated Chief Executive Officer of BioNTech<\/b>. \u201cI am deeply honored to be leading BioNTech and prioritizing its evolution into a global biopharmaceutical company with multiple approved products by 2030, while continuing to advance its innovative pre-clinical and clinical portfolio in line with the Company\u2019s strategy. I look forward to joining my colleagues on the Management Board and our teams worldwide on the journey ahead to deliver on BioNTech’s patient-centric strategy and create sustainable, long-term value.\u201d<\/p>\n

\u201cBioNTech is in a pivotal phase as the Company focuses on advancing its diversified pipeline into approved products and sustainable medical benefits for patients. I have come to know Guido Oelkers as a leader who combines a deep understanding of the pharmaceutical industry and strong strategic acumen with genuine respect for the culture and people of our organization,\u201d said Prof. Ugur Sahin, M.D., Chief Executive Officer and Co-Founder of BioNTech<\/b>. \u201cWith Guido Oelkers taking over, I feel confident that BioNTech is in a strong position to realize its vision. To ensure a smooth and successful handover, I will be actively supporting his onboarding.\u201d<\/p>\n

The appointment of the new CEO is the result of a comprehensive selection process led by the Supervisory Board. As previously announced, BioNTech\u2019s Chief Medical Officer, Prof. \u00d6zlem T\u00fcreci, M.D., will transition into the management of a new, independent company, which she will lead together with her husband and co-founder, Prof. Ugur Sahin, M.D. The search for her successor is ongoing and focuses on identifying a leader with exceptional medical and scientific expertise, extensive experience in late-stage clinical development, and a proven track record of advancing innovative platforms and complex product candidates.<\/p>\n

\n About Guido Oelkers <\/b>
\n
Guido Oelkers, Ph.D., is an accomplished executive who has served multiple times as CEO throughout his career at both publicly traded companies and private equity portfolio companies in Europe and the Asia-Pacific region. Most recently, he has served as CEO of Swedish Orphan Biovitrum AB (\u201cSobi\u201d), where he more than quadrupled the company\u2019s revenues over a nine-year period (financial years 2017 to 2026). During his tenure, he significantly increased Sobi\u2019s profitability and strengthened its late-stage pipeline, positioning the company for sustained long-term success. Prior to joining Sobi, he served as CEO of the medical technology manufacturer BSN Medical Holding GmbH, as President and CEO of the Swedish medtech company Gambro AB and as CEO of the specialty pharmaceutical company Invida Holdings Pte. Ltd. Guido Oelkers held a number of executive roles in companies such as Nycomed International Management GmbH, DKSH Group, Aventis Pharma S.A. China and Hoechst AG, where he started his career. He holds a PhD in Business Management from Adelaide University, Australia, and completed his undergraduate and postgraduate studies in business management and economics in Mainz and London, respectively. Guido Oelkers is a German citizen and will be based in BioNTech\u2019s headquarters in Mainz, Germany.<\/p>\n

A photo of Guido Oelkers (\u00a9 Sobi – Swedish Orphan Biovitrum AB (publ), 2026) is available for download here<\/a>. <\/p>\n

\n About BioNTech<\/b>
\n
BioNTech is a global next generation biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases. In oncology, BioNTech is committed to transforming how cancer is treated. Its ambition is to develop innovative medicines with pan-tumor or synergistic potential to address cancer from multiple angles and across the full continuum of the disease from early- to late-stage. Its growing late-stage oncology pipeline comprises complementary treatment approaches spanning immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies. BioNTech has partnered with multiple global and specialized pharmaceutical collaborators leveraging complementary expertise and resources to accelerate innovation and drive progress, including Bristol Myers Squibb, Duality Biologics, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, and Pfizer.<\/p>\n

For more information, please visit www.BioNTech.com<\/a>.<\/p>\n

\n BioNTech Forward-Looking Statements<\/b>
\n
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: expected changes to BioNTech\u2019s leadership and the potential benefits of BioNTech\u2019s leadership hires; BioNTech\u2019s research and development programs; BioNTech\u2019s focus on building commercial capabilities for potential market launches; and BioNTech\u2019s expectations regarding the timing of, ability to obtain and maintain regulatory approval of, and planned readiness for, such launches. In some cases, forward-looking statements can be identified by terminology such as \u201cwill,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201caims,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors, many of which are beyond BioNTech\u2019s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: discussions with regulatory agencies regarding timing and requirements for additional clinical trials; the ability to produce comparable clinical results in future clinical trials; competition related to BioNTech\u2019s product candidates, including those with different mechanisms of action and different manufacturing and distribution constraints, on the basis of, among other things, efficacy, cost, convenience of storage and distribution, breadth of approved use, side-effect profile and durability of immune response; the timing of and BioNTech\u2019s ability to obtain and maintain regulatory approval for BioNTech\u2019s product candidates; BioNTech\u2019s and its counterparties\u2019 ability to manage and source necessary resources; BioNTech\u2019s ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech\u2019s third-party collaborators to continue research and development activities relating to BioNTech\u2019s development candidates and investigational medicines; BioNTech\u2019s and its collaborators\u2019 ability to commercialize and market its product candidates, if approved; BioNTech\u2019s ability to manage its development and expansion; regulatory developments in the United States and other countries and regions; BioNTech\u2019s ability to effectively scale its production capabilities and manufacture its product candidates; and other factors not known to BioNTech at this time.<\/p>\n

You should review the risks and uncertainties described under the heading \u201cRisk Factors\u201d in BioNTech\u2019s Report on Form 6-K for the period ended March 31, 2026, and in subsequent filings made by BioNTech with the SEC, which are available on the SEC\u2019s website at www.sec.gov. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise.<\/p>\n

\n CONTACTS<\/b>\n <\/p>\n

\n Media Relations<\/b>
\n
Jasmina Alatovic
Media@biontech.de<\/a><\/p>\n

\n Investor Relations<\/b>
\n
Douglas Maffei, Ph.D.
Investors@biontech.de<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Mainz, Germany, August 3, 2026 (GLOBE NEWSWIRE) \u2013 BioNTech SE (Nasdaq: BNTX, \u201cBioNTech\u201d or \u201cthe Company\u201d) announced today that its Supervisory Board has appointed Guido Oelkers, Ph.D., to the Management Board as Chief Executive Officer (\u201cCEO\u201d), who will take office by February 1, 2027, at the latest. Succeeding Prof. Ugur Sahin, M.D., Guido Oelkers will join BioNTech from the global Nasdaq Stockholm-listed biopharmaceutical company Swedish Orphan Biovitrum AB (STO: SOBI, \u201cSobi\u201d), where he has served as CEO since 2017. Guido Oelkers is a seasoned CEO and strategic leader with over 30 years of experience in the biotechnology and pharmaceutical industries. He has a strong track record in transforming and scaling global organizations, driving sustainable growth through disciplined execution, focused capital … <\/p>\n

Continue reading “BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-988239","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-appointment-of-guido-oelkers-to-management-board-as-chief-executive-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Mainz, Germany, August 3, 2026 (GLOBE NEWSWIRE) \u2013 BioNTech SE (Nasdaq: BNTX, \u201cBioNTech\u201d or \u201cthe Company\u201d) announced today that its Supervisory Board has appointed Guido Oelkers, Ph.D., to the Management Board as Chief Executive Officer (\u201cCEO\u201d), who will take office by February 1, 2027, at the latest. Succeeding Prof. Ugur Sahin, M.D., Guido Oelkers will join BioNTech from the global Nasdaq Stockholm-listed biopharmaceutical company Swedish Orphan Biovitrum AB (STO: SOBI, \u201cSobi\u201d), where he has served as CEO since 2017. Guido Oelkers is a seasoned CEO and strategic leader with over 30 years of experience in the biotechnology and pharmaceutical industries. He has a strong track record in transforming and scaling global organizations, driving sustainable growth through disciplined execution, focused capital … Continue reading "BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-appointment-of-guido-oelkers-to-management-board-as-chief-executive-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-03T09:03:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI1NTcxOSM0MDI0ODIyNzEjMjAwMDk4NQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-appointment-of-guido-oelkers-to-management-board-as-chief-executive-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-appointment-of-guido-oelkers-to-management-board-as-chief-executive-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer\",\"datePublished\":\"2026-08-03T09:03:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-appointment-of-guido-oelkers-to-management-board-as-chief-executive-officer\\\/\"},\"wordCount\":1391,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-appointment-of-guido-oelkers-to-management-board-as-chief-executive-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTI1NTcxOSM0MDI0ODIyNzEjMjAwMDk4NQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-appointment-of-guido-oelkers-to-management-board-as-chief-executive-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-appointment-of-guido-oelkers-to-management-board-as-chief-executive-officer\\\/\",\"name\":\"BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-appointment-of-guido-oelkers-to-management-board-as-chief-executive-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-appointment-of-guido-oelkers-to-management-board-as-chief-executive-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTI1NTcxOSM0MDI0ODIyNzEjMjAwMDk4NQ==\",\"datePublished\":\"2026-08-03T09:03:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-appointment-of-guido-oelkers-to-management-board-as-chief-executive-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-appointment-of-guido-oelkers-to-management-board-as-chief-executive-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-appointment-of-guido-oelkers-to-management-board-as-chief-executive-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTI1NTcxOSM0MDI0ODIyNzEjMjAwMDk4NQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTI1NTcxOSM0MDI0ODIyNzEjMjAwMDk4NQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-appointment-of-guido-oelkers-to-management-board-as-chief-executive-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-appointment-of-guido-oelkers-to-management-board-as-chief-executive-officer\/","og_locale":"en_US","og_type":"article","og_title":"BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer - Market Newsdesk","og_description":"Mainz, Germany, August 3, 2026 (GLOBE NEWSWIRE) \u2013 BioNTech SE (Nasdaq: BNTX, \u201cBioNTech\u201d or \u201cthe Company\u201d) announced today that its Supervisory Board has appointed Guido Oelkers, Ph.D., to the Management Board as Chief Executive Officer (\u201cCEO\u201d), who will take office by February 1, 2027, at the latest. Succeeding Prof. Ugur Sahin, M.D., Guido Oelkers will join BioNTech from the global Nasdaq Stockholm-listed biopharmaceutical company Swedish Orphan Biovitrum AB (STO: SOBI, \u201cSobi\u201d), where he has served as CEO since 2017. Guido Oelkers is a seasoned CEO and strategic leader with over 30 years of experience in the biotechnology and pharmaceutical industries. He has a strong track record in transforming and scaling global organizations, driving sustainable growth through disciplined execution, focused capital … Continue reading \"BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-appointment-of-guido-oelkers-to-management-board-as-chief-executive-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-03T09:03:01+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI1NTcxOSM0MDI0ODIyNzEjMjAwMDk4NQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-appointment-of-guido-oelkers-to-management-board-as-chief-executive-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-appointment-of-guido-oelkers-to-management-board-as-chief-executive-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer","datePublished":"2026-08-03T09:03:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-appointment-of-guido-oelkers-to-management-board-as-chief-executive-officer\/"},"wordCount":1391,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-appointment-of-guido-oelkers-to-management-board-as-chief-executive-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI1NTcxOSM0MDI0ODIyNzEjMjAwMDk4NQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-appointment-of-guido-oelkers-to-management-board-as-chief-executive-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-appointment-of-guido-oelkers-to-management-board-as-chief-executive-officer\/","name":"BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-appointment-of-guido-oelkers-to-management-board-as-chief-executive-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-appointment-of-guido-oelkers-to-management-board-as-chief-executive-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI1NTcxOSM0MDI0ODIyNzEjMjAwMDk4NQ==","datePublished":"2026-08-03T09:03:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-appointment-of-guido-oelkers-to-management-board-as-chief-executive-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-appointment-of-guido-oelkers-to-management-board-as-chief-executive-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-appointment-of-guido-oelkers-to-management-board-as-chief-executive-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI1NTcxOSM0MDI0ODIyNzEjMjAwMDk4NQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTI1NTcxOSM0MDI0ODIyNzEjMjAwMDk4NQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-appointment-of-guido-oelkers-to-management-board-as-chief-executive-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/988239","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=988239"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/988239\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=988239"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=988239"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=988239"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}